NTRK gene fusions: a rough diamond ready to sparkle

Affiliations

¹ Thoracic Oncology Department and Early Phase Clinical Trials Section, and Marlene and Stewart Greenebaum Comprehensive Cancer Center, School of Medicine, Maryland University, Baltimore, MD 21201, USA. Electronic address: crolfo@som.umaryland.edu.

Comment

Christian Rolfo. Lancet Oncol. 2020 Apr.

. 2020 Apr;21(4):472-474.

doi: 10.1016/S1470-2045(20)30026-7. Epub 2020 Feb 24.

¹ Thoracic Oncology Department and Early Phase Clinical Trials Section, and Marlene and Stewart Greenebaum Comprehensive Cancer Center, School of Medicine, Maryland University, Baltimore, MD 21201, USA. Electronic address: crolfo@som.umaryland.edu.

No abstract available

Comment on

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Hong DS, et al. Lancet Oncol. 2020 Apr;21(4):531-540. doi: 10.1016/S1470-2045(19)30856-3. Epub 2020 Feb 24. Lancet Oncol. 2020. PMID: 32105622 Free PMC article. Clinical Trial.